Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden - Scorecard - MDSpire
Advertisement
Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden
Clinical Scorecard: Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction: Early and Lasting Improvements Regardless of Initial Type 2 Inflammation Levels and Nasal Polyp Severity
At a Glance
Category
Detail
Condition
Chronic rhinosinusitis with nasal polyps (CRSwNP) and olfactory dysfunction (OD)
Key Mechanisms
Inhibition of IL-4 receptor signaling
Target Population
Adults with moderate-to-severe olfactory dysfunction due to CRSwNP
Care Setting
Real-world clinical setting
Key Highlights
40 patients with moderate-to-severe OD received stapokibart 300 mg every 2 weeks for 16 weeks.
52.5% of patients achieved normosmia by Week 16.
Significant olfactory improvement observed by Week 2 (P<0.0001).
Olfactory recovery consistent across subgroups regardless of baseline inflammatory markers.
Higher baseline polyp burden correlated with faster early improvement.
Guideline-Based Recommendations
Diagnosis
Endoscopic confirmation of CRSwNP and assessment of olfactory dysfunction.
Management
Use of stapokibart for patients inadequately controlled by conventional therapies.
Monitoring & Follow-up
Assess olfactory outcomes using smell loss VAS and SSIT-16 at multiple time points.
Risks
Consider potential adverse effects of traditional interventions like corticosteroids and surgery.
Patient & Prescribing Data
Adults with endoscopically confirmed CRSwNP and moderate-to-severe OD.
Stapokibart shows rapid and sustained improvement in olfactory function.
Clinical Best Practices
Monitor olfactory function and polyp scores during treatment.
Consider baseline characteristics when personalizing treatment strategies.
